Literature DB >> 11828884

Protein "AGEing"--cytotoxicity of a glycated protein increases with its degree of AGE-modification.

J Gasic-Milenkovic1, C Loske, W Deuther-Conrad, G Münch.   

Abstract

Non-enzymatic glycation of proteins with reducing sugars and subsequent transition metal-catalyzed oxidations leads to the formation of protein-bound "advanced glycation endproducts" (AGEs). They accumulate on long-lived proteins including on and in the vicinity of the beta-amyloid plaques in Alzheimer's disease (AD). Since the AGE modification of a protein increases with time, and such a "long-term incubation" might also occur in the AD brain, we investigated whether an increase in the cytotoxic effects of an AGE-modified model protein occurs over time. Bovine serum albumin (BSA) was modified by glucose for defined time periods, and the viability of SH-SY5Y neuroblastoma cells, incubated with the differentially AGE-modified BSA samples, was measured with the MTT assay. Cytotoxicity of the AGE-modified BSAs increased in correlation to the incubation time with glucose. Among the AGE-specific markers, browning (OD 400) correlated best with cytotoxicity, followed by AGE-specific fluorescence and the defined AGE, carboxymethyllysine. Since AGEs accumulate in AD over time, they may be one of the "age-related" factors contributing to neuronal cell death in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11828884     DOI: 10.1007/s003910170018

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  6 in total

1.  RAGE-Specific Inhibitor FPS-ZM1 Attenuates AGEs-Induced Neuroinflammation and Oxidative Stress in Rat Primary Microglia.

Authors:  Chao Shen; Yingjuan Ma; Ziling Zeng; Qingqing Yin; Yan Hong; Xunyao Hou; Xueping Liu
Journal:  Neurochem Res       Date:  2017-06-29       Impact factor: 3.996

2.  Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury.

Authors:  Li Wang; Chun-jiang Yu; Wei Liu; Lu-yang Cheng; Yi-na Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-07-18       Impact factor: 6.150

Review 3.  The receptor for advanced glycation endproducts is a mediator of toxicity by IAPP and other proteotoxic aggregates: Establishing and exploiting common ground for novel amyloidosis therapies.

Authors:  Andisheh Abedini; Julia Derk; Ann Marie Schmidt
Journal:  Protein Sci       Date:  2018-07       Impact factor: 6.725

4.  The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal.

Authors:  Julie Webster; Christin Urban; Katrin Berbaum; Claudia Loske; Alan Alpar; Ulrich Gärtner; Susana Garcia de Arriba; Thomas Arendt; Gerald Münch
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 5.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

6.  The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease.

Authors:  Shun-Yao Ko; Hshin-An Ko; Kuo-Hsiung Chu; Tzong-Ming Shieh; Tzong-Cherng Chi; Hong-I Chen; Weng-Cheng Chang; Shu-Shing Chang
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.